Unleashing the Power of IL-17: A Promising Frontier in Chronic Obstructive Pulmonary Disease (COPD) Treatment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Aerospace Engineering
Reference14 articles.
1. Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy;Kramer JM;J Periodontol,2007
2. Targeting Interleukin-17 signalling in cigarette smoke-induced lung disease: mechanistic concepts and therapeutic opportunities;Roos AB;Pharmacol Ther,2017
3. T2 biologics for chronic obstructive pulmonary disease;Yousuf A;J Allergy Clin Immunol Pract,2019
4. MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling;Hao R;Am J Physiol Lung Cell Mol Physiol,2019
5. An inhibitor of RORγ for chronic pulmonary obstructive disease treatment;Desai H;Sci Rep,2022
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives;International Journal of Molecular Sciences;2024-07-04
2. Evidence construction of Jinshuibao capsules against stable chronic obstructive pulmonary disease: A systematic review and network pharmacology;Heliyon;2024-07
3. Effect of Humidified High-Flow Nasal Cannula Oxygen Therapy with a Pulmonary Infection Control Window as a Ventilation Switching Indication in Combination with Atomizing Inhalation of Terbutaline on the Lung Function of Patients with Acute Exacerbation of COPD;ACTA MED OKAYAMA;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3